Vivoryon Therapeutics N.V.
https://www.vivoryon.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vivoryon Therapeutics N.V.
Vivoryon Brings 'Diversity' To Therapeutic Approach In Alzheimer’s
Ulrich Dauer, CEO Vivoryon Therapeutics, the new name for German biotech Probiodrug, talks to In Vivo about introducing more diversity into the Alzheimer’s disease pipeline.
Interview: Vivoryon Raises €43m After Alzheimer's Revival
New life has been breathed into Alzheimer's research following the reversal of fortunes for Biogen's aducanumab and Vivoryon is benefiting from the upturn in sentiment for the field.
Vivoryon And MorphoSys Link To Accelerate Novel Small Molecule Checkpoint Silencing Approach
Vivoryon CEO explains how QPCTL-targeting small molecule technology will be tested for combination with MorphoSys’s tafasitamab to enhance cancer-killing efficacy.
Probiodrug CEO Outlines Phase IIb Plans For Potential Alzheimer’s Treatments
Probiodrug is ramping up plans to run Phase IIb Alzheimer's disease trials on the back of biomarker data that indicates that its approach to targeting pyroglutamate-Abeta is a promising therapeutic strategy. CEO Konrad Glund spoke to Scrip at the 2018 Biotech Showcase.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Probiodrug AG
- Vivoryon Therapeutics AG